As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has launched an investigation into reports of serious adverse events, including one fatality, associated
Three-year-old Oliver Chu has stunned clinicians after becoming the first person with Hunter syndrome (MPS II) to receive an experimental gene therapy and showing striking
Editor’s Note: Patient Worthy is pleased to share this article from our friends at Elephants & Tea, originally written by Cecily Liu. To see the
The United Leukodystrophy Foundation (ULF) is proud and excited to announce a partnership with Marc Nolan, a Chicago-based footwear brand, who is launching a new
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, for adults with neurofibromatosis
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from
The FDA has approved two "biosimilars," increasing access to potentially life-saving medication at a potentially more cost-effective rate. Read more here:
patientworthy.com/2026/01/08/fda-approves-amneals-denosumab-biosimilars-boncresa-and-oziltus/
Results from a promising study suggest smarter breast cancer screening is on the way. Read more here:
patientworthy.com/2026/01/08/risk-based-breast-cancer-screening-shows-promise-in-major-u-s-study/
What increases DLBCL risk? Age, HIV, autoimmune diseases... swipe to learn more, and share your story with us here: bit.ly/4dV7gru #DLBCL #dlbclriskfactors #PatientWorthy
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
